

# Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/T26B0C08890EN.html>

Date: December 2019

Pages: 88

Price: US\$ 3,500.00 (Single User License)

ID: T26B0C08890EN

## Abstracts

Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2019

### SUMMARY

Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF- $\beta$ 1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.

Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 26 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 9 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Respiratory, Cardiovascular, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Ophthalmology, Central Nervous System, Genetic Disorders, Hematological Disorders and Metabolic Disorders which include indications Fibrosis, Idiopathic Pulmonary Fibrosis, Breast Cancer, Kidney Fibrosis, Osteoarthritis, Solid Tumor, Squamous Cell Carcinoma, Anemia, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Bone

Disorders, Cholangitis, Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hepatocellular Carcinoma, Hyperalgesia, Hypertrophic Scars, Inflammation, Liver Fibrosis, Lung Adenocarcinoma, Melanoma, Metastatic Breast Cancer, Myelofibrosis, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Nonmelanomatous Skin Cancer, Open-Angle Glaucoma, Osteogenesis Imperfecta, Pancreatic Cancer, Pancreatitis Pain, Peripheral Artery Occlusive Disease (PAOD), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Primary Sclerosing Cholangitis, Proliferative Vitreoretinopathy (PVR), Pulmonary Hypertension, Scar and Systemic Sclerosis (Scleroderma).

The latest report Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2019, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)

The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and

collaboration details & other developmental activities

The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects

The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Transforming Growth Factor Beta 1 (TGFB1) - Overview

Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics Development

AlfaSigma SpA

Avacta Life Sciences Ltd

Bonac Corp

Ensol Biosciences Inc

Forbius

Genzyme Corp

Huabo Biopharm Co Ltd

Isarna Therapeutics GmbH

Johnson & Johnson

Novartis AG

Phio Pharmaceuticals Corp

Scholar Rock Inc

Sirnaomics Inc

Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles

Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotides to Inhibit TGFB1 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVA-027 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVID-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNC-1021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

decorin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Engedi-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluorofenidone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fresolimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISTH-1047 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISTH-1106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melittin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Latent TGFB1 for Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit TGF Beta1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit TGFB1 for Oncology, Gastrointestinal and Genito  
Urinary System and Sex Hormones Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody 1 to Inhibit TGFB1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit TGF-Beta-1 for Chronic Pancreatitis Pain and  
Hyperalgesia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit TGFB1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit TGF Beta 1 for Squamous Cell Carcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit TGFB1 for Camurati-Engelmann Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Small Molecule to Inhibit TGFB1 for Idiopathic Pulmonary Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### SRK-181 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### STP-705 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### sulodexide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### XOMA-089 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

### Transforming Growth Factor Beta 1 (TGFB1) - Dormant Products

### Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products

### Transforming Growth Factor Beta 1 (TGFB1) - Product Development Milestones

#### Featured News & Press Releases

Nov 08, 2019: Forbius completes phase 1 oncology dose-escalation with AVID200, first-in-class TGF-beta 1 & 3 inhibitor: Well tolerated, target inhibition demonstrated at all dose levels, data reported at SITC

Nov 06, 2019: Sirnaomics to Present Overview of Company's RNAi Technology Platform at Upcoming Conferences

Nov 05, 2019: Forbius to report phase 1a oncology clinical data with AVID200, first-in-class TGF-beta 1 & 3 inhibitor, in late-breaking poster presentation

Oct 31, 2019: Sirnaomics to present preclinical STP705 data suggesting reduction in Liver Fibrosis at AASLD Liver Meeting

Oct 14, 2019: Forbius completes enrollment into phase 1a solid tumor trial of AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor; Closes Series C Financing

Sep 28, 2019: ESMO 2019: Forbius demonstrates target engagement in Phase 1 immuno-oncology clinical trial with AVID200, first-in-class TGF-beta 1 & 3 Inhibitor

Sep 23, 2019: Forbius announces AVID200, a first-in-class TGF-beta 1 & 3 selective inhibitor, to be featured at ESMO and CICON 2019



May 16, 2019: Sirnaomics publishes data for lead candidate STP705 in Cancer Model as 2019 American Society of Clinical Oncology Annual Meeting Online Abstract

Apr 29, 2019: Forbius' AVID200, a Novel TGF-beta 1 & 3 inhibitor, cleared by Health Canada to commence phase 1 clinical trial in Solid Tumors

Apr 24, 2019: Forbius: First patient dosed in a phase 1b Myelofibrosis trial of AVID200, a novel TGF-beta 1 & 3 inhibitor

Apr 08, 2019: Sirnaomics to present at World Orphan Drug Congress 2019

Apr 02, 2019: Scholar Rock presents additional preclinical data demonstrating a highly specific inhibitor of TGF $\beta$ 1 activation can render resistant solid tumors vulnerable to PD1 blockade and drive tumor regression with combination therapy

Mar 12, 2019: Scholar Rock to develop cancer immunotherapy product candidate, SRK-181, a selective inhibitor of TGF $\beta$ 1 activation, to overcome checkpoint inhibitor resistance

Mar 04, 2019: Forbius announces the first patient dosed in a phase 1b diffuse cutaneous systemic sclerosis trial of AVID200, a novel TGF-beta 1 & 3 inhibitor

Mar 04, 2019: Forbius announces the first patient dosed in a phase 1b diffuse scleroderma trial of AVID200, a novel TGF-beta 1 & 3 inhibitor

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indications, H2 2019  
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Products under Development by Companies, H2 2019 (Contd..2), H2 2019  
Number of Products under Investigation by Universities/Institutes, H2 2019  
Products under Investigation by Universities/Institutes, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by AlfaSigma SpA, H2 2019  
Pipeline by Avacta Life Sciences Ltd, H2 2019  
Pipeline by Bonac Corp, H2 2019  
Pipeline by Ensol Biosciences Inc, H2 2019  
Pipeline by Forbius, H2 2019  
Pipeline by Genzyme Corp, H2 2019  
Pipeline by Huabo Biopharm Co Ltd, H2 2019  
Pipeline by Isarna Therapeutics GmbH, H2 2019  
Pipeline by Johnson & Johnson, H2 2019  
Pipeline by Novartis AG, H2 2019  
Pipeline by Phio Pharmaceuticals Corp, H2 2019  
Pipeline by Scholar Rock Inc, H2 2019  
Pipeline by Sirnaomics Inc, H2 2019  
Dormant Products, H2 2019  
Dormant Products, H2 2019 (Contd..1), H2 2019  
Dormant Products, H2 2019 (Contd..2), H2 2019  
Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

### COMPANIES MENTIONED

AlfaSigma SpA

Avacta Life Sciences Ltd

Bonac Corp

Ensol Biosciences Inc

Forbius

Genzyme Corp

Huabo Biopharm Co Ltd

Isarna Therapeutics GmbH

Johnson & Johnson

Novartis AG

Phio Pharmaceuticals Corp

Scholar Rock Inc

Sirnaomics Inc

## I would like to order

Product name: Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/T26B0C08890EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T26B0C08890EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970